WWC2 is an independent prognostic factor and prevents invasion via Hippo signalling in hepatocellular carcinoma

Yijun Zhang a, b, Shumei Yan a, b, Jiewei Chen a, b, Caixia Gan a, b, Dong Chen c, Yan Li d, Jiahuai Wen e, Joachim Kremerskothen f, Shilu Chen a, b, Jiangbo Zhang a, *, Yun Cao a, b, *

a Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China
b Department of Pathology, Sun Yat-Sen University Cancer Center, Guangzhou, China
c Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China
d Department of Oncology, Tumor Angiogenesis and Microenvironment Laboratory (TAML), First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China
e Department of Breast Oncology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China
f Internal Medicine D, Department of Nephrology, Hypertension and Rheumatology, University Hospital Muenster, Muenster, Germany

Received: January 19, 2017; Accepted: May 23, 2017

Abstract

WWC family proteins negatively regulate HEK293 cell proliferation and organ growth by suppressing the transcriptional activity of Yes-associated protein (YAP), a major effector of the Hippo pathway. The function of the scaffolding protein WWC1 (also called KIBRA) has been intensively studied in cells and animal models. However, the expression and clinicopathologic significance of WWC2 in cancer are poorly characterized. This study aimed to clarify the biological function and mechanism of action of WWC2 in hepatocellular carcinoma (HCC). Retrospective analysis revealed WWC2 was significantly down-regulated in 95 clinical HCC tissues compared to the paired adjacent non-cancerous tissues. Moreover, loss of WWC2 expression was significantly associated with advanced clinicopathological features, including venous infiltration, larger tumour size and advanced TNM stage. Positive WWC2 expression was associated with significantly better 5-year overall survival, and WWC2 was an independent prognostic factor for overall survival in HCC. Moreover, we confirmed WWC2 inhibits HCC cell invasive ability in vitro. Elevated YAP expression was also observed in the same cohort of HCC tissues. Pearson’s correlation coefficient analysis indicated WWC2 expression correlated inversely with nuclear YAP protein expression in HCC. Mechanistically, we confirmed overexpression of WWC2 suppresses the invasive and metastatic potential of HCC cells by activating large tumour suppressor 1 and 2 kinases (LATS1/2), which in turn phosphorylates the transcriptional co-activator YAP. Overall, this study indicates WWC2 functions as a tumour suppressor by negatively regulating the Hippo signalling pathway and may serve as a prognostic marker in HCC.

Keywords: WWC2 • YAP • LATS2 • hepatocellular carcinoma • hippo pathway

Introduction

Hepatocellular carcinoma (HCC) is the fifth most common cancer and third leading cause of cancer-related deaths worldwide [1], and its incidence is increasing. Surgical reaction and liver transplantation are currently the best curative options for HCC. However, recurrence or metastasis is relatively common after resection [2]. Multiple signalling pathways contribute to the development of HCC. Recently, the Hippo pathway has been found to be involved in cell size regulation, cell proliferation, cell death and tumorigenesis of HCC [3-6].

The Hippo pathway contains a number of tumour suppressors and oncogenes. Core components and upstream regulators such as...
LATS1/2 and mammalian Ste20-like kinases 1 and 2 (MST1/2) predominantly function as tumour suppressors, whereas PDZ-binding Motif (TAZ), Yes-associated protein (YAP) and (TEA)-domain family members (TEADs) promote oncogenic events [7–9]. YAP is a pivotal effector of the Hippo pathway [10, 11]. Previous studies identified YAP was an independent prognostic marker, and inactivation of the Hippo pathway was significantly associated with poorer prognosis in HCC [12]. Moreover, overexpression of YAP induces the epithelial–mesenchymal transition (EMT), growth factor-independent cell proliferation and oncogenesis [13–15]. In mammals, several tumour suppressors (Mst1/2, Sav1/WW45, Lats1/2, Mob1) regulate the transcriptional co-activator YAP, forming a kinase cascade that culminates in phosphorylation and inactivation of YAP [16–18]. Unphosphorylated YAP localizes to the nucleus, where it serves as a co-activator for TEAD DNA-binding transcription factors [19, 20]. Although the Hippo pathway is well characterized, the ability of upstream regulators of this pathway to function as oncogenic drivers in HCC remains largely unknown.

Recent studies in Drosophila melanogaster and mammalian cells identified WW-and-C2-domain-containing protein (WWC) family proteins as regulatory elements of the Hippo pathway [21, 22]. WWC family members include WWC1 (also known as KIBRA), WWC2 and WWC3 [23]. Similarly to the other two WWC family members, WWC2 contains two amino terminal WW domains that mediate binding to target proteins harbouring L/PpXY motifs, as well as an internal C2 domain for membrane association [22]. WWC proteins can negatively regulate Hippo signalling by activating the LATS1/2 kinases, which in turn phosphorylate YAP and prevent its nuclear import, which negatively regulates cell proliferation and regulates tissue growth in mammalian cells [21, 22, 24, 25]. Wennmann and colleagues identified WWC proteins enhance phosphorylation of LATS1/2 and YAP, reduce the transcriptional activity of YAP and impair cell proliferation in HEK293 cells [22]. Although the function of WWC1 has been studied intensively in cells and animal models, our understanding of the expression, biological behaviour and molecular mechanisms of action of WWC2 remains limited, particularly in human cancer.

In view of the ability of WWC2 to regulate the transcriptional activity of YAP by activating LATS1/2 in HEK293 cells, we suggested that WWC2 may also inhibit cell invasion in HCC by negatively regulating Hippo signalling. In this study, we aimed to explore the relationship between WWC2 and the clinicopathologic features of HCC and define the role of WWC2 in regulation of the Hippo signalling pathway in HCC.

**Clinical samples**

Tumour samples and paired normal tumour-adjacent samples (~2 cm distance from the margin of the resection) from 95 patients with HCC treated between 2000 and 2006 were obtained from the archives of the Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, China. The cases were selected based on the following criteria: pathological diagnosis of HCC; primary and curative tumour resection without pre-operative or post-operative anticancer treatment; and availability of resection tissue and follow-up data. The HCC cohort included 83 (87.4%) males and 12 (12.6%) females with a mean age of 49.0 years. The patients were followed up every 3 months after surgery for the first year, every 6 months for the next 2 years, then annually; all patients were followed up for at least 2 years. The clinicopathologic features summarized in Table 1 include age, gender, hepatitis history, serum alpha-fetoprotein (AFP) level, presence of cirrhosis, number of lesions, tumour size, level of tumour differentiation, tumour stage, extent of vascular invasion and capsule invasion. Tumour differentiation and stage were defined according to the tumour-node-metastasis (TNM) classification system of the American Joint Committee on Cancer/International Union Against Cancer. Overall survival was calculated from the date of diagnosis to the date of death. The other 24 fresh HCC tissues and adjacent non-tumour tissues samples were obtained from 24 patients who underwent surgical resection for HCC at Sun Yat-sen University Cancer Center. All samples were frozen in liquid nitrogen immediately after resection and stored at −80°C until use.

**Cell culture**

Human HCC cell lines QGY-7703, QGY-7701, SMMC-7721, MHCC-97L, MHCC-97H, HepG2, Bel-7402 and Bel-7404 and the human normal liver cell line L02 were purchased from the Cell Resource Center, Chinese Academy of Science Committee (Shanghai, China). Cells were cultured in RPMI-1640 medium containing 10% foetal bovine serum at 37°C in a humidified atmosphere of 5% CO2.

**Plasmid construction and transfection**

Expression plasmids for pCDNA-3x-Flag-WWC2 (encoding a triple Flag-tagged WWC2 protein and kanamycin resistance gene) and V180-3x-Flag (control vector, encodes only the 3x-Flag tag and kanamycin resistance gene) were obtained from Kremerskothen [22]. The sequences of the WWC2 siRNA (Guangzhou Ruibo Co. Ltd, Guangzhou, China) were as follows: si-h-WWC2: GAGCCAGATTTGAGATGTA. The wild-type (WT) LATS2 and various LATS2 mutant expression plasmids were obtained from Dr. Dong [21]. Cells were transiently transfected with WWC2 siRNA and various plasmids using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions.

**Immunohistochemistry**

The paraffin-embedded samples were serially cut into 4-μm-thick sections, de-paraffinized in xylene, rehydrated through a graded alcohol series, immersed in 3% hydrogen peroxide for 10 min. to block endogenous peroxidase activity and subjected to antigen retrieval by...
pressure cooking for 3 min. in citrate buffer (pH 6.0). Then, the slides were incubated with 10% normal goat serum at room temperature for 30 min. to reduce non-specific reactivity and then incubated with rabbit polyclonal anti-WWC2 antibody (1:100; Abcam, Cambridge, MA, USA) or rabbit monoclonal anti-YAP antibody (1:100, cat.14074; Cell Signaling Technology, Boston, MA, USA) overnight at 4°C. Slides were washed twice with PBS for 5 min., incubated with a secondary antibody (Envision; Dako, Glostrup, Denmark) for 1 hr at room temperature, washed twice with PBS for 5 min. and developed using 3,3-diaminobenzidine (DAB). Finally, the sections were counterstained with Mayer’s haematoxylin, dehydrated and mounted. Negative controls were prepared by replacing the primary antibody with normal murine IgG.

All sections were scored independently by two experienced pathologists. The labelling score was obtained by multiplying the score for the percentage of positively stained cells ['0' (<5%), '1' (6–25%), '2' (26–50%), '3' (51–75%), '4' (76–100%)] by the score for staining intensity ['0' (negative staining), '1' (weak staining), '2' (moderate staining) and '3' (strong staining)] to give a final score for each section. Sections with a total score of ≥4 were defined as exhibiting positive staining.

Nuclear YAP positivity was scored by determining the percentage of positive nuclei regardless of cytoplasmic YAP expression and staining intensity.

Western blotting

Western blotting was performed as previously described [26]. Protein samples (50 μg) were separated by SDS-PAGE (10%) and transferred to a polyvinylidene fluoride (PVDF) membranes (Millipore, Billerica, MA, USA) and incubated overnight at 4°C with the following antibodies: YAP (1:500, cat. 14074), pYAP-S127 (1:500, cat. 57706), vimentin (1:1,000, cat. 12826), snail (1:500, cat. 3895) (Cell Signaling Technology), Flag (1:5,000, cat. F3165), c-myc (1:5,000, cat. M5546) (Sigma-Aldrich, St. Louis, MO, USA), LATS1/2 (1:500, cat. ab70565), pLATS1/2 (phospho T1079 + T1041; 1:500, cat. ab111344; Abcam), E-cadherin (1:500, cat. 610181) and N-cadherin (1:1,000, cat. 610920; BD Transduction Laboratories, Lexington, KY, USA). After incubation with anti-mouse (1:2,000, E030110-01) or anti-rabbit (1:2,000, E030120-01) IgG antibodies (EarthOx LLC, San Francisco, CA, USA) at 37°C for 2 hrs, the protein bands were visualized using enhanced chemiluminescence (ECL; Thermo Fisher Scientific, Waltham, MA, USA) and quantified using a

### Table 1. Clinical characteristics and WWC2 expression for 95 cases of hepatocellular carcinoma

| Characteristic | Patients | WWC2 | P-value |
|---------------|----------|------|---------|
|               |          | Negative (%) | Positive (%) |
| Age (years)   |          |                 |             |
| <60           | 47       | 30              | 17         | 0.939   |
| ≥60           | 48       | 31              | 17         |          |
| Gender        |          |                 |             |
| Male          | 83       | 54              | 29         | 0.650   |
| Female        | 12       | 7               | 5          |          |
| HBV           |          |                 |             |
| Absent        | 10       | 5               | 5          | 0.322   |
| Present       | 85       | 56              | 29         |          |
| Cirrhosis     |          |                 |             |
| Absent        | 15       | 7               | 8          | 0.122   |
| Present       | 80       | 54              | 26         |          |
| Tumour size (cm) |      |                 |             |
| <5            | 24       | 11              | 13         |          |
| ≥5            | 71       | 50              | 21         | 0.030*  |
| Serum AFP (ng/ml) |    |                 |             |
| <400          | 57       | 37              | 20         |          |
| ≥400          | 38       | 24              | 14         | 0.861   |
| No. of tumour nodules | | | |
| 1             | 81       | 50              | 31         |          |
| ≥2            | 14       | 11              | 3          | 0.225   |
| Differentiation |        |                 |             |
| Well          | 7        | 4               | 3          |          |
| Moderate      | 43       | 28              | 15         |          |
| Poor          | 45       | 29              | 16         | 0.919   |
| Capsule invasion |      |                 |             |
| Absent        | 63       | 39              | 24         |          |
| Present       | 32       | 22              | 10         | 0.511   |
| Venous infiltration | | | |
| Absent        | 71       | 40              | 31         |          |

| Characteristic | Patients | WWC2 | P-value |
|---------------|----------|------|---------|
|               |          | Negative (%) | Positive (%) |
| Present       | 24       | 21              | 3          | 0.006*  |
| TNM stage     |          |                 |             |
| I + II        | 67       | 35              | 32         | 0.001*  |
| III + IV      | 28       | 26              | 2          |          |

HCC, hepatocellular carcinoma; HBV, hepatitis B virus; AFP, alpha-fetoprotein; TNM, tumour-node-metastasis.

*Statistically significant.
BioImaging Systems platform (UVP, Upland, CA, USA). Relative protein levels were calculated using GAPDH as the loading control.

**Real-time quantitative RT-PCR**

Total RNA was extracted from cells using TRIzol reagent according to the manufacturer’s protocol. Next, cDNA was synthesized from 1 μg of total RNA by a PrimerScript RT Reagent kit (TaKaRa, Dalian, China). Real-time quantitative RT-PCR was performed using a SYBR green PCR master mix in an Applied Biosystems StepOne and StepOne-Plus Real-Time PCR system (Applied Biosystems, Foster City, CA, USA). The primers used for real-time PCR were shown in Table S1. The gene expression ΔCt values of mRNA from each sample were calculated by normalizing with the reference gene 18s. All experiments were repeated in triplicate to confirm the findings.

**Matrigel cell invasion assay**

Matrigel cell invasion assays were performed using 8-μm polycarbonate membranes (Corning, Acton, MA, USA) according to the manufacturer’s instructions. Cell suspension (5 × 10⁶ cells; 100 μl) was added to the upper chamber, while the lower chamber was filled with RPMI-1640 medium containing 10% foetal calf serum. The plates were incubated for 24 hrs, and then cells that had invaded to the lower membrane surface were fixed in methanol for 30 min. and stained with haematoxylin (Sigma). For each filter, the numbers of cells that invaded to the lower surface of the membrane were counted in five randomly selected fields of view at 200 × magnification using a Nikon E200 light microscope (Nikon, Melville, NY, USA). Mean cell numbers were calculated from the data obtained from each experiment repeated three times.

**Statistical analysis**

SPSS statistical software (standard version 16.0; SPSS, Chicago, IL, USA) was used to perform the Pearson chi-squared test, Kaplan–Meier analysis and log-rank tests. GraphPad Prism 5 software (GraphPad Software, Inc., San Diego, CA, USA) was used to perform two-tailed Student’s t-tests. P < 0.05 was considered statistically significant.

**Results**

**Down-regulation of WWC2 protein expression is clinically significant in HCC**

Initially, we performed immunohistochemistry on 95 paired tumour samples and paired normal tumour-adjacent samples obtained during liver resection from patients with HCC. WWC2 expression was detected in 93.7% (89/95) of the matched non-cancerous tissue samples, whereas only 35.8% (34/95) of the HCC specimens demonstrated positive WWC2 expression (P < 0.001). Furthermore, Western blotting of 24 paired HCC tissues and adjacent non-tumour tissues confirmed WWC2 protein expression was significantly down-regulated in HCC compared to non-cancerous tissues. WWC2 expression was significantly lower in HCC tissues than in normal tumour-adjacent tissues (***P < 0.001, t-test). Western blot (C) and quantitative analyses (D) of WWC2 expression in LO-2 cells and eight HCC cell lines (***P < 0.001, t-test). Kaplan–Meier overall survival curves for 95 patients with HCC stratified by WWC2 expression; positive WWC2 expression was associated with better overall survival (***P < 0.001, log-rank test).

Fig. 1 WWC2 is down-regulated and clinically significant in hepatocellular carcinoma (HCC). (A, B) Representative Western blot (A) and quantitative analysis (B) of WWC2 expression in 24 paired HCC (T) and matched adjacent non-tumour tissues (NT); values are mean ± standard error of the mean. WWC2 protein expression was significantly lower in HCC tissues than in normal tumour-adjacent tissues (***P < 0.001, t-test). (C, D) Western blot (C) and quantitative analyses (D) of WWC2 expression in LO-2 cells and eight HCC cell lines (***P < 0.001, t-test). (E) Kaplan–Meier overall survival curves for 95 patients with HCC stratified by WWC2 expression; positive WWC2 expression was associated with better overall survival (***P < 0.001, log-rank test).
decreased in HCC tissues compared with the paired adjacent non-tumour tissues \((P < 0.001;\) Fig. 1A and B). Retrospective clinical association analysis using the Pearson chi-squared test revealed decreased WWC2 expression in HCC was positively associated with tumour size \((P = 0.030)\), venous infiltration \((P = 0.006)\) and advanced tumour stage \((TNM, P = 0.001;\) Table 1).

To further confirm WWC2 is down-regulated in HCC, we performed Western blotting of eight HCC cell lines and the normal liver cell line LO2. The expression of WWC2 was significantly lower in all eight HCC cell lines than LO2 cells \((P < 0.001;\) Fig. 1C and D).

**Positive WWC2 expression correlates with better 5-year survival in HCC**

Next, we examined the prognostic value of WWC2 for overall survival in HCC. Kaplan–Meier survival curves \(\log-rank = 15.836; P = 0.000)\); overall survival was 45.0% for WWC2-negative HCC compared to 52.9% for WWC2-positive HCC. Multivariate Cox regression indicated that, in addition to tumour stage \((TNM, P = 0.015)\) and the number of tumour nodules \((P = 0.041)\), WWC2 expression was an independent prognostic factor for overall survival in HCC \((P = 0.003;\) Table 2).

**Overexpression of WWC2 inhibits the invasion of HCC cells**

To investigate the effect of WWC2 on invasion in HCC, we selected cells expressing low levels \((SMMC-7721 cells)\) and high levels of WWC2 \((HepG2 cells)\) for further studies. Western blot analysis demonstrated overexpression of WWC2 using an expression vector increased E-cadherin expression and decreased N-cadherin, vimentin and snail expression in SMMC-7721 cells \((P = 0.006, P = 0.02, P = 0.0005, P = 0.0015,\) respectively; Fig. 2A). Conversely, knockdown of WWC2 using a siRNA decreased E-cadherin expression and increased N-cadherin, vimentin and snail expression in HepG2 cells \((P = 0.005, P = 0.016, P = 0.007, P = 0.021,\) respectively; Fig. 2B).

Moreover, overexpression of WWC2 reduced the invasive ability of SMMC-7721 cells \((52.0 \pm 1.20 vs. 33.33 \pm 1.50, P < 0.001;\) Fig. 2C), whereas knockdown of WWC2 enhanced the invasive ability of HepG2 cells \((18.0 \pm 0.82 vs. 39.6 \pm 0.65, P < 0.01;\) Fig. 2D).

**Positive WWC2 expression correlates negatively with nuclear YAP protein in HCC tissues**

As the transcriptional co-activator YAP can be located in both the cytoplasm and nucleus \([12, 27]\), we examined the associations between WWC2 expression and cytoplasmic and nuclear YAP expression in HCC. Nuclear YAP expression was significantly lower in HCC than the paired non-cancerous tissues \([72.6% (69/95) vs. 32.6% (31/95); P = 0.027]\). On the contrary, cytoplasmic YAP expression was significantly lower in HCC tissues \([50.5% (48/95) vs. 67.4% (64/95); P = 0.006]\). Immunohistochemistry scores were generated for quantitative analysis of WWC2 and YAP expression in the 95 HCC samples. WWC2 expression correlated negatively with cytoplasmic YAP expression \((P = 0.014)\) and positively with nuclear YAP expression \((P = 0.045;\) Fig. 3C-F and Table 3).

**WWC2 negatively regulates Hippo signalling in HCC by activating LATS2, which in turn phosphorylates YAP**

To further characterize the function of WWC2 and to explore the relationship between WWC2 and the Hippo signalling pathway in HCC, we analysed the phosphorylation status of LATS1/2 and YAP, major components of the Hippo pathway. Western blot analysis revealed phosphorylation of both LATS1/2 and YAP significantly increased at 48 hrs in HCC cells transfected with the WWC2 overexpression plasmid \((P = 0.007 and P = 0.0045,\) respectively, compared to cells transfected with vector control plasmid and untreated cells; Fig. 4A). Conversely, the levels of p-LATS1/2 and p-YAP were lower in HepG2 cells transfected with the WWC2 siRNA than cells transfected with the NC-siRNA \((P = 0.005 and P = 0.031;\) Fig. 4B). In addition, it has been reported that several genes are regulated by YAP, including connective tissue growth factor \((CTGF)\) and Cyr61 \([28–31]\). We next examined the mRNA levels of the two genes by real-time quantitative
RT-PCR. As shown in Figure 4C, overexpressing WWC2 was sufficient to suppress the expression of CTGF and Cyr61 at the mRNA level. On the contrast, HepG2 cells transfected with si-WWC2 showed an increased mRNA level of CTGF and Cyr61 (Fig. 4D). Together, these results suggest WWC2 regulates the Hippo pathway in HCC by phosphorylating LATS1/2 and YAP. LATS1/2 can inactivate YAP by phosphorylating the serine 127 residue of YAP [32, 33]. To confirm WWC2 promotes phosphorylation of

Fig. 2 Overexpression of WWC2 reduces the invasive ability of hepatocellular carcinoma (HCC) cells. (A) SMCC-7721 cells transiently transfected with the WWC2 plasmid showed increased E-cadherin expression and decreased N-cadherin, vimentin and snail expression. (B) Knockdown of WWC2 decreased E-cadherin expression and increased N-cadherin, snail and vimentin expression in HepG2 cells. (C) Transient transfection of WWC2 into SMCC-7721 cells decreased cell invasive ability (**P < 0.01). (D) Knockdown of WWC2 enhanced the invasive ability of HepG2 cells (**P < 0.01, t-test).
YAP by activating the LATS1/2 kinases in HCC, we cotransfected SMMC-7721 cells with the WWC2 expression plasmid and WT LATS2 or various LATS2 mutants. As shown in Figure 4C, cotransfection of the kinase-dead form of LATS2 (K697R mutant) markedly blocked WWC2-stimulated YAP phosphorylation (compare lane 5 with lanes 2 to 4; \( P = 0.001, P = 0.0003, P = 0.0001 \), respectively). The non-phosphorylatable mutant form (LATS2 with both S872A and T1041A mutations) partially blocked YAP phosphorylation compared to the LATS2-KD mutant (\( P = 0.0006; \) Fig. 4C). Thus, our data indicate WWC2 negatively regulates the Hippo pathway in HCC by activating

**Fig. 3** WWC2 is down-regulated and correlates inversely with Yes-associated protein (YAP) nuclear expression in human hepatocellular carcinoma (HCC). (A, B) Representative photomicrographs of WWC2 immunohistochemistry in HCC tissues and the matched adjacent non-tumour tissues. In the adjacent liver tissues, WWC2 expression was generally positive (A) with cytoplasmic YAP expression (B). (C, D) In cases of HCC with high WWC2 protein expression (C), low nuclear YAP protein expression and strong cytoplasmic YAP protein expression were observed (D). (E, F) In cases of HCC with low WWC2 protein expression (E), low cytoplasmic YAP protein expression and strong nuclear YAP protein expression were observed (F).
Table 3. Associations between WWC2 expression and nuclear and cytoplasmic Yes-associated protein (YAP) expression in hepatocellular carcinoma

| Patients | WWC2 expression | Nuclear YAP expression | Cytoplasmic YAP expression |
|----------|----------------|-----------------------|---------------------------|
|          | Negative  | Positive  | Positive  | Negative  | Positive  |
|          | 26       | 11        | 15        | 7.473    | 0.006*   |
|          | 69       | 50        | 19        | 6.209    | 0.013*   |

HCC, hepatocellular carcinoma. *Statistically significant.

LATS2, which in turn phosphorylates the transcriptional co-activator YAP and prevents its nuclear translocation.

**WWC2 suppresses the invasive ability of HCC cells by negatively regulating Hippo signalling**

To determine whether the ability of WWC2 to regulate Hippo signalling affects invasion in HCC, SMMC-7721 cells, which express low levels of WWC2, were cotransfected flag-WWC2 and WT LATS2 or various LATS2 mutants. Western blot analysis demonstrated cotransfection of the kinase-dead form LATS2 mutant (LATS2-KD) decreased E-cadherin expression and increased N-cadherin, vimentin and snail expression, compared to SMMC-7721 cells cotransfected with LATS2-WT (P = 0.0001, 0.0002, 0.0001, 0.0004, respectively; Fig. 5A). Transfection of the non-phosphorylatable mutant form of LATS2 (LATS2 with both S872A and T1041A mutations) partially inhibited the EMT compared with the LATS2-KD mutant (P = 0.0002 for E-cadherin, P = 0.0028 for N-cadherin, P = 0.0014 for vimentin and P = 0.0111 for snail, respectively; Fig. 5A). Cotransfection of LATS2-KD also reduced the invasive ability of SMMC-7721 cells compared to cotransfection of LATS2-WT (P = 0.0023; Fig. 5B). Moreover, the non-phosphorylatable mutant form (LATS2 with both S872A and T1041A mutations) partially inhibited invasion compared to cells transfected with the kinase-inactive LATS2-KD mutant (P = 0.0012; Fig. 5B). Taken together, these data indicate that WWC2 suppresses the EMT and invasion in HCC cells by negatively regulating the Hippo signalling pathway.

**Discussion**

WWC family proteins negatively regulate Hippo signalling by activating the LATS1/2 kinases, which in turn phosphorylate the transcriptional co-activator YAP and prevents its nuclear translocation in mammalian cells [21, 25, 34, 35]. Wennmann et al. subsequently verified endogenous LATS1/2 kinases bind to all types of WWC proteins in HEK293 cells [22]. In drosophila, loss of KIBRA function increased proliferation, reduced apoptosis and regulated Hippo signalling targets; these changes are the typical phenotypes associated with loss of function of Hippo components [36–38]. However, these studies focused on Kibra/WWC1, and the biological effects and molecular mechanisms of action of WWC2 in cancer remained unclear. This study indicates WWC2 negatively regulates the Hippo pathway in HCC, implying WWC2 may represent a candidate target protein for cancer therapeutics.

First, we demonstrated WWC2 protein expression was significantly down-regulated in HCC compared with the matched adjacent non-tumour tissues, and the absence of WWC2 expression was significantly associated with larger tumour size, venous infiltration and advanced TNM tumour stage. Moreover, positive WWC2 expression was associated with significantly better 5-year overall survival and WWC2 was an independent prognostic factor for 5-year overall survival, which suggests WWC2 functions as a tumour suppressor in HCC. These findings indicate assessment of WWC2 expression may help to determine the prognosis of patients with HCC. Furthermore, we confirmed that WWC2 suppresses tumour progression by inhibiting the invasive ability of HCC cells.

WWC2 has been reported to be involved in Hippo signalling [22]. As YAP is a pivotal effector of the Hippo pathway, we examined the correlation between WWC2 and YAP protein expression in HCC tissues. The function of the transcriptional co-activator YAP varies depending on its subcellular localization [12, 27]. WWC2 expression correlated negatively with nuclear YAP expression and positively with cytoplasmic YAP expression in HCC. This data further indicate WWC2 functions as tumour suppressor by acting as an upstream regulator of YAP in the Hippo signalling pathway, and this relationship plays a role in the development of HCC; further studies are required to clarify the role of WWC2 in the development of cancer.
WWC2 can suppress cell proliferation and organ growth by activating members of the Hippo tumour suppressor pathway, including LATS1/2. Wennmann et al. have verified WWC2 directly binds to LATS1/2 via their WW domains, and phosphorylates and activates LATS1/2 [22]. Activated LATS1/2 phosphorylate YAP, which inhibited cell proliferation in mammalian cells [38, 39, 40]. In confirmation that WWC2 activates the Hippo pathway in HCC, overexpression of WWC2 in SMMC-7721 cells (which express low levels of WWC2)
Fig. 5 WWC2 suppresses the invasive ability of hepatocellular carcinoma (HCC) cells by activating LATS2, which in turn phosphorylates Yes-associated protein (YAP). (A) Western blot analysis showing cotransfection with WWC2 and LATS2-KD decreased E-cadherin expression and increased N-cadherin, vimentin and snail expression in SMMC-7721 cells compared to cotransfection with LATS2-WT (P = 0.0001, P = 0.0002, P = 0.0001, P = 0.0004, respectively). The LATS2-ST partially inhibited the epithelial mesenchymal transition (EMT) compared to the LATS2-KD (P = 0.0002 for E-cadherin, P = 0.0028 for N-cadherin, P = 0.0014 for vimentin and P = 0.0111 for snail, respectively). (B) Cotransfection of the LATS2-KD also reduced cell invasion compared to SMMC-7721 cells cotransfected with LATS2-WT (P = 0.0023). The LATS2-ST partially inhibited cell invasion, as compared with the LATS2-KD mutant (P = 0.0012). WT, wild type; KD, kinase-dead form (K697R); ST, LATS2 with both S872A and T1041A mutations.
increased phosphorylation of both LATS and YAP, which has been previously shown to negatively regulate the Hippo pathway [11, 41, 42]. The latter study also revealed HCC cells transfected with the WWC2 overexpression plasmid decreased the mRNA level of Cyr61 and CTGF, both of which are the target genes of Hippo pathway. All these very well-confirmed overexpressing WWC2 negatively regulate the Hippo pathway.

In agreement with previous studies [22], we confirmed WWC2 phosphorylates LATS1/2, which in turn phosphorylates YAP in HCC cells. Indeed, cotransfection of WWC2 with a kinase-inactive form (LATS2-KD, K687R mutant) or non-phosphorylatable mutant form (LATS2 with both S872A and T1041A mutations) provided a relatively objective model to verify WWC2 regulates YAP phosphorylation by activating the LATS2 kinase. Phosphorylated YAP cannot translocate to the nucleus, where it serves as a co-activator for the TEA-domain family member (TEAD) group of DNA-binding transcription factors activating the LATS2 kinase. Phosphorylated YAP cannot translocate to the nucleus, where it serves as a co-activator for the TEA-domain family member (TEAD) group of DNA-binding transcription factors activating the LATS2 kinase. Phosphorylated YAP cannot translocate to the nucleus, where it serves as a co-activator for the TEA-domain family member (TEAD) group of DNA-binding transcription factors activating the LATS2 kinase. Phosphorylated YAP cannot translocate to the nucleus, where it serves as a co-activator for the TEA-domain family member (TEAD) group of DNA-binding transcription factors activating the LATS2 kinase. Phosphorylated YAP cannot translocate to the nucleus, where it serves as a co-activator for the TEA-domain family member (TEAD) group of DNA-binding transcription factors activating the LATS2 kinase. Phosphorylated YAP cannot translocate to the nucleus, where it serves as a co-activator for the TEA-domain family member (TEAD) group of DNA-binding transcription factors activating the LATS2 kinase. Phosphorylated YAP cannot translocate to the nucleus, where it serves as a co-activator for the TEA-domain family member (TEAD) group of DNA-binding transcription factors activating the LATS2 kinase. Phosphorylated YAP cannot translocate to the nucleus, where it serves as a co-activator for the TEA-domain family member (TEAD) group of DNA-binding transcription factors activating the LATS2 kinase. Phosphorylated YAP cannot translocate to the nucleus, where it serves as a co-activator for the TEA-domain family member (TEAD) group of DNA-binding transcription factors activating the LATS2 kinase. Phosphorylated YAP cannot translocate to the nucleus, where it serves as a co-activator for the TEA-domain family member (TEAD) group of DNA-binding transcription factors activating the LATS2 kinase. Phosphorylated YAP cannot translocate to the nucleus, where it serves as a co-activator for the TEA-domain family member (TEAD) group of DNA-binding transcription factors activating the LATS2 kinase. Phosphorylated YAP cannot translocate to the nucleus, where it serves as a co-activator for the TEA-domain family member (TEAD) group of DNA-binding transcription factors activating the LATS2 kinase. Phosphorylated YAP cannot translocate to the nucleus, where it serves as a co-activator for the TEA-domain family member (TEAD) group of DNA-binding transcription factors activating the LATS2 kinase. Phosphorylated YAP cannot translocate to the nucleus, where it serves as a co-activator for the TEA-domain family member (TEAD) group of DNA-binding transcription factors activating the LATS2 kinase. Phosphorylated YAP cannot translocate to the nucleus, where it serves as a co-activator for the TEA-domain family member (TEAD) group of DNA-binding transcription factors activating the LATS2 kinase. Phosphorylated YAP cannot translocate to the nucleus, where it serves as a co-activator for the TEA-domain family member (TEAD) group of DNA-binding transcription factors activating the LATS2 kinase. Phosphorylated YAP cannot translocate to the nucleus, where it serves as a co-activator for the TEA-domain family member (TEAD) group of DNA-binding transcription factors activating the LATS2 kinase. Phosphorylated YAP cannot translocate to the nucleus, where it serves as a co-activator for the TEA-domain family member (TEAD) group of DNA-binding transcription factors activating the LATS2 kinase. Phosphorylated YAP cannot translocate to the nucleus, where it serves as a co-activator for the TEA-domain family member (TEAD) group of DNA-binding transcription factors activating the LATS2 kinase. Phosphorylated YAP cannot translocate to the nucleus, where it serves as a co-activator for the TEA-domain family member (TEAD) group of DNA-binding transcription factors activating the LATS2 kinase. Phosphorylated YAP cannot translocate to the nucleus, where it serves as a co-activator for the TEA-domain family member (TEAD) group of DNA-binding transcription factors activating the LATS2 kinase. Phosphorylated YAP cannot translocate to the nucleus, where it serves as a co-activator for the TEA-domain family member (TEAD) group of DNA-binding transcription factors activating the LATS2 kinase. Phosphorylated YAP cannot translocate to the nucleus, where it serves as a co-activator for the TEA-domain family member (TEAD) group of DNA-binding transcription factors activating the LATS2 kinase. Phosphorylated YAP cannot translocate to the nucleus, where it serves as a co-activator for the TEA-domain family member (TEAD) group of DNA-binding transcription factors activating the LATS2 kinase. Phosphorylated YAP cannot translocate to the nucleus, where it serves as a co-activator for the TEA-domain family member (TEAD) group of DNA-binding transcription factors activating the LATS2 kinase.

In conclusion, we demonstrate that down-regulation of WWC2 is associated with the clinicopathological features of advanced HCC. Negative WWC2 expression was an independent prognostic factor for poor survival in HCC. Moreover, WWC2 suppresses the invasion and metastatic potential of HCC cells by negatively regulating the Hippo signalling pathway by phosphorylating LATS2, which in turn phosphorylates and inhibits nuclear translocation of the transcriptional co-activator YAP. These findings indicate WWC2 may represent a potential therapeutic target for HCC.

Acknowledgements

This work was supported by a grant from the National Natural Science Foundation of China [grant number: 81502056 and 81472380]. YJZ, SMY, JWC, CXG, DC, JHW and SLC performed the research; YJZ, SMY, YL and JBZ analysed the data and wrote the manuscript; YC and JBZ contributed to design the research study and submitted the final version with approval. We are particularly grateful to Dr. Joachim Kremerskothen for providing the plasmid of flag-WWC2 and to Dr. Jixin Dong for proving the plasmids wild-type (WT) LATS2 and various LATS2 provided.

Conflict of Interest

The authors declare that they have no conflict of interests.

Supporting information

Additional Supporting Information may be found online in the supporting information tab for this article:

Table S1 Primer sequences for quantitative real-time RT-PCR.

References

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003; 362: 1907–17.

2. Liu AM, Poon RT, Luk JM. Microma-375 targets hippo-signaling effector yap in liver cancer and inhibits tumor properties. Biochem Biophys Res Commun. 2010; 394: 623–7.

3. Li H, Wolfe A, Septer S, et al. Deregulation of hippo kinase signalling in human hepatic malignancies. Liver Int. 2012: 32: 38–47.

4. Apte U, Gkretsi V, Bowen WC, et al. Enhanced liver regeneration following changes induced by hepatocyte-specific genetic ablation of integrin-linked kinase. Hepatology. 2009; 50: 844–51.

5. Sohn BH, Shim JJ, Kim SB, et al. Inactivation of hippo pathway is significantly associated with poor prognosis in hepatocellular carcinoma. Clin Cancer Res. 2016; 22: 1256–64.

6. Wu H, Wei L, Fan F, et al. Integration of hippo signalling and the unfolded protein response to restrain liver overgrowth and tumorigenesis. Nat Commun. 2015; 6: 6239.

7. Ganem NJ, Comils H, Chiu SY, et al. Cytokinesis failure triggers hippo tumor suppressor pathway activation. Cell. 2014; 158: 833–48.

8. Yu FX, Guan KL. The hippo pathway: regulators and regulations. Genes Dev. 2013; 27: 355–71.

9. Mo JS, Park HW, Guan KL. The hippo signaling pathway in stem cell biology and cancer. EMBO Rep. 2014; 15: 642–56.

10. Cao X, Pfaff SL, Gage FH. Yap regulates neural progenitor cell number via the tea domain transcription factor. Genes Dev. 2008; 22: 3320–34.

11. Huang J, Wu S, Barrera J, et al. The hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating yorke, the drosophila homolog of yap. Cell. 2005; 122: 421–34.

12. Xu MZ, Yao TJ, Lee NP, et al. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer. 2009; 115: 4576–85.

13. Shao DD, Xue W, Krali EB, et al. Kras and yap1 converge to regulate emt and tumor survival. Cell. 2014; 158: 171–84.

14. Yuan Y, Li D, Li H, et al. Yap overexpression promotes the epithelial-mesenchymal transition and chemoresistance in pancreatic cancer cells. Mol Med Rep. 2016; 13: 237–42.

15. Wang S, Li H, Wang G, et al. Yes-associated protein (yap) expression is involved in epithelial-mesenchymal transition in hepato-cellular carcinoma. Clin Transl Oncol. 2016; 18: 172–7.

16. Song H, Mak KK, Topol L, et al. Mammalian mst1 and mst2 kinases play essential roles in organ size control and tumor suppression. Proc Natl Acad Sci U S A. 2010; 107: 1431–6.

17. Zhang N, Bai H, David KK, et al. The merlin/mt2 tumor suppressor functions through the yap oncoprotein to regulate tissue homeostasis in mammals. Dev Cell. 2010; 19: 27–38.

18. Nishioka N, Inoue K, Adachi K, et al. The hippo signaling pathway components lats and yap pattern tead4 activity to distinguish mouse trophectoderm from inner cell mass. Dev Cell. 2009; 16: 398–410.

19. Liu-Chittenden Y, Huang B, Shim JS, et al. Genetic and pharmacological disruption of the tead-yap complex suppresses the...
oncogenic activity of yap. *Genes Dev.* 2012; 26: 1300–5.
20. Harvey KF, Zhang X, Thomas DM. The hippo pathway and human cancer. *Nat Rev Cancer.* 2013; 13: 246–57.
21. Xiao L, Chen Y, Ji M, et al. Kibra regulates hippo signaling activity via interactions with large tumor suppressor kinases. *J Biol Chem.* 2011; 286: 7788–96.
22. Wennmann DG, Schmitz J, Wehr MC, et al. Evolutionary and molecular facts link the wwc protein family to hippo signaling. *Mol Biol Evol.* 2014; 31: 1710–23.
23. Kremerskothen J, Plaas C, Buther K, et al. Kibra functions as a tumor suppressor protein that regulates hippo signaling in conjunction with merlin and expanded. *Dev Cell.* 2010; 18: 288–99.
24. Zhao B, Li L, Tumaneng K, et al. Rassf1a-mediated regulation of areg via the hippo pathway in hepatocellular carcinoma. *Oncogene.* 2013; 32: 1821–30.
25. Stauffer S, Chen X, Zhang L, et al. Kibra promotes prostate cancer cell proliferation and motility. *FEBS J.* 2016; 283: 1800–11.
26. Wilson KE, Li YW, Yang N, et al. Ptn14 forms a complex with kibra and lats1 proteins and negatively regulates the yap oncogenic function. *J Biol Chem.* 2014; 289: 23893–700.
27. Yu J, Zheng Y, Dong J, et al. Kibra functions as a tumor suppressor protein that regulates hippo signaling in conjunction with merlin and expanded. *Dev Cell.* 2010; 18: 288–99.
28. Oka T, Mazack V, Sudol M. Mst2 and lats kinases regulate apoptotic function of yes kinase-associated protein (yap). *J Biol Chem.* 2008; 283: 27534–46.
29. Zhao B, Li L, Tumaneng K, et al. A coordinated phosphorylation by lats and ck1 regulates yap stability through scf(beta-trcp). *Genes Dev.* 2010; 24: 72–85.
30. Hergovich A, Hemmings BA. Mammalian ndr/lats protein kinases in hippo tumor suppressor signaling. *BioFactors.* 2009; 35: 338–45.
31. Ahn EY, Kim JS, Kim GJ, et al. Ptn14-mediated regulation of areg via the hippo pathway in hepatocellular carcinoma. *Mol Cancer Res.* 2013; 11: 748–58.